Drop in peripheral blood Epstein-Barr virus nucleic acid loads after post-transplant lymphoproliferative disorders associates with better 5-year event-free survival: results from the multicenter PTLD-MSMS study.

被引：0
|
作者：
Dharnidharka, Vikas [1 ]
Jaza, Lujain [1 ]
Agarwal, Mansi [1 ]
Goss, Charles [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
来源：
TRANSPLANTATION | 2024年 / 108卷 / 9S期
关键词：
D O I：
10.1097/01.tp.0001064332.01029.ef
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
222.2
引用
收藏
页数：1
相关论文
共 5 条
  • [1] Drop in peripheral blood Epstein-Barr virus nucleic acid loads after post-transplant lymphoproliferative disorders associates with better 5-year event-free survival: results from the multicenter PTLD-MSMS study
    Dharnidharka, Vikas
    Jaza, Lujain
    Agarwal, Mansi
    Goss, Charles
    TRANSPLANTATION, 2024, 108 (09) : 38 - 38
  • [2] Early presentation of post-transplant lymphoproliferative disorders (PTLD) or tumor positivity for epstein-barr virus does not confer better patient survival: A multicenter pediatric series
    Green, Michael
    Marks, Lianna
    Storch, Gregory A.
    Dharnidharka, Vikas R.
    PEDIATRIC TRANSPLANTATION, 2022, 26
  • [3] RISK FACTORS OF EPSTEIN-BARR VIRUS REACTIVATION AND POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN THE FIRST YEAR AFTER KIDNEY TRANSPLANTATION: RESULTS FROM A LARGE MULTICENTRE STUDY
    Blazquez-Navarro, A.
    Dang-Heine, C.
    Bauer, C.
    Wittenbrink, N.
    Wolk, K.
    Sabat, R.
    Westhoff, T. H.
    Sawitzki, B.
    Viebahn, R.
    Reinke, P.
    Or-Guil, M.
    Thomusch, O.
    Hugo, C.
    Babel, N.
    TRANSPLANT INTERNATIONAL, 2018, 31 : 22 - 22
  • [4] RISK FACTORS OF EPSTEIN-BARR VIRUS REACTIVATION AND POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS DURING THE FIRST YEAR AFTER KIDNEY TRANSPLANTATION: RESULTS FROM A LARGE MULTI-CENTRE STUDY
    Blazquez-Navarro, Arturo
    Bauer, Chris
    Sawitzki, Birgit
    Viebahn, Richard
    Westhoff, Timm
    Reinke, Petra
    Thomusch, Oliver
    Hugo, Christian
    Or-Guil, Michal
    Babel, Nina
    TRANSPLANT INTERNATIONAL, 2019, 32 : 392 - 392
  • [5] New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
    Mahadeo, Kris Michael
    Baiocchi, Robert A.
    Beitinjaneh, Amer
    Chaganti, Sridhar
    Choquet, Sylvain
    Dierickx, Daan
    Dinavahi, Rajani
    Gamelin, Laurence
    Ghobadi, Armin
    Guzman-Becerra, Norma
    Joshi, Manher
    Mehta, Aditi
    Nikiforow, Sarah
    Reshef, Ran
    Ye, Wei
    Prockop, Susan
    BLOOD, 2022, 140 : 10374 - 10376
1